European journal of clinical investigation
-
Eur. J. Clin. Invest. · Nov 2021
ReviewRecent advances in pharmacological treatment of heart failure.
Over the last years, several trials offered new evidence on heart failure (HF) treatment. ⋯ This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.
-
Eur. J. Clin. Invest. · Nov 2021
TNF-α antagonism rescues the effect of ageing on stroke: Perspectives for targeting inflamm-ageing.
Epidemiologic evidence links ischemic stroke to age, yet the mechanisms that underlie the specific and independent effects of age on stroke remain elusive, impeding the development of targeted treatments. This study tested the hypothesis that age directly aggravates stroke outcomes and proposes inflamm-aging as a mediator and potential therapeutic target. ⋯ This study identifies TNF-α as a causative contributor to the deleterious effect of aging on stroke and points to inflamm-aging as a mechanism of age-related worsening of stroke outcomes and potential therapeutic target in this context. Thus, this work provides a basis for tailoring novel stroke therapies for the particularly vulnerable elderly population.
-
Currently, we remain uncertain about which patients are at increased risk for recurrent pericarditis. We developed a risk score for pericarditis recurrence in patients with acute pericarditis. ⋯ A simple risk score point system based on 6 variables can be used to predict the individualized risk for pericarditis recurrence among patients with a first episode of acute pericarditis.
-
Eur. J. Clin. Invest. · Nov 2021
Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients.
COVID-19 has a wide spectrum of cardiovascular sequelae including myocarditis and pericarditis; however, the prevalence and clinical impact are unclear. We investigated the prevalence of new-onset myocarditis/pericarditis and associated adverse cardiovascular events in patients with COVID-19. ⋯ Patients with COVID-19 who present with myocarditis/pericarditis associate with increased odds of major adverse events and new-onset cardiovascular sequelae.